# Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

> **NCT04002674** · PHASE2 · COMPLETED · sponsor: **Georgetown University** · enrollment: 43 (actual)

## Conditions studied

- Dementia With Lewy Bodies

## Interventions

- **DRUG:** Placebo oral capsule
- **DRUG:** Nilotinib Oral Capsule

## Key facts

- **NCT ID:** NCT04002674
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04002674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04002674, "Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04002674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*